We sell the NBS option we bought Friday this morning for .95

NBS Nov 2014 7.500 call (NBS141122C00007500)

 -OPR  Watchlist

0.95  0.06(6.74%) 11:29AM EST

Prev Close:	0.89
Open:	0.90
Bid:	0.90
Ask:	0.95
Strike:	7.50
Expire Date:	22-Nov-14

Now what about that put I was talking about? Forget about it. They are not only annoucing Phase 2 at a conference today, but are going to be talking at conferences the entire last part of November and that means hype hype hype with people purchasing the stock:

NEW YORK, Nov. 12, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS), a biopharmaceutical company developing novel cell based therapeutics, announced today that the Company will present at multiple upcoming investor conferences in late November in addition to its presentation at the American Heart Association Scientific Sessions of data from the Phase 2 PreSERVE AMI clinical trial evaluating NBS10 in the treatment of damaged heart muscle following a heart attack.

Stifel 2014 Healthcare Conference

• Date and Time: Tuesday, November 18, 2014, 4:10 PM EST
• Venue: New York Palace Hotel, New York, New York
• Presenter: Dr. Robin Smith, Chairman and Chief Executive Officer, NeoStem, Inc.
• Topic: Company Presentation

Jefferies 2014 Global Healthcare Conference

• Date and Time: Thursday, November 20, 2014, 5:00 PM GMT
• Venue: Waldorf Hilton, London, United Kingdom
• Website: http://www.jefferies.com/OurFirm/Conferences/325/170
• Presenter: Dr. Robin Smith, Chairman and Chief Executive Officer, NeoStem, Inc.
• Topic: Company Presentation

Deutsches Eigenkapitalforum (German Equity Forum 2014)

• Date and Time: Tuesday, November 25, 5:30 PM CET
• Venue: Congress Center Messe Frankfurt, Frankfurt, Germany
• Website: http://www.eigenkapitalforum.com/index.php?lang=en
• Presenter: Robert Dickey IV, Chief Financial Officer, NeoStem, Inc.
• Topic: Company Presentation

So: what else have we today....I will be back later today with another pick. Once again, we are not going to do the put thing with NBS, and we have sold the call.

Happy Trading,
Mark